European Companies Search Engine
EU funding (€8,689,222): Early Interception of Inflammatory-mediated Type 2 Diabetes Hor1 Dec 2022 EU Research and Innovation programme "Horizon"
Overview
Text
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: Olatec Therapeutics B.V., New York-FL, United States.
The visualizations for "Olatec Therapeutics B.V. - EU funding (€8,689,222): Early Interception of Inflammatory-mediated Type 2 Diabetes"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.